Weed (BUDZ) Net Cash Flow Growth (1y) (2011 - 2026)
Weed (BUDZ) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.15 Bn | 87.28 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.16 Bn | 1.97 Bn | 112.26% |
| 3 | Zoetis | 32.68 Bn | 30.74 Bn | 1.62 Bn | -44.11% |
| 4 | Takeda Pharmaceutical | 27.59 Bn | 23.53 Bn | 4.39 Bn | 209.30% |
| 5 | United Therapeutics | 23.21 Bn | 21.06 Bn | 648.10 Mn | -236.85% |
| 6 | RedHill Biopharma | 20.54 Bn | 20.54 Bn | - | - |
| 7 | Viatris | 20.31 Bn | 18.50 Bn | 1.16 Bn | 13,485.29% |
| 8 | Neurocrine Biosciences | 17.83 Bn | 16.51 Bn | 800.70 Mn | -1,047.81% |
| 9 | Elanco Animal Health | 12.60 Bn | 12.17 Bn | 785.00 Mn | -1,020.00% |
| 10 | Weed | 2.77 Mn | 2.77 Mn | - | 81.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 81.72% |
| Dec 31, 2025 | -78.73% |
| Sep 30, 2025 | 48.96% |
| Jun 30, 2025 | 103.83% |
| Mar 31, 2025 | 16.83% |
| Dec 31, 2024 | 143.37% |
| Sep 30, 2024 | -101.47% |
| Jun 30, 2024 | 25.25% |
| Mar 31, 2024 | 14.65% |
| Dec 31, 2023 | -61.13% |
| Sep 30, 2023 | 332.15% |
| Jun 30, 2023 | 75.43% |
| Mar 31, 2023 | -1,567.39% |
| Dec 31, 2022 | -1,326.26% |
| Sep 30, 2022 | -690.64% |
| Jun 30, 2022 | -8,967.41% |
| Mar 31, 2022 | -52.66% |
| Dec 31, 2021 | 111.64% |
| Sep 30, 2021 | -122.69% |
| Jun 30, 2021 | -306.96% |